Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

Praveen Ramakrishnan Geethakumari, Dheepthi Perumal Ramasamy, Bhagirathbhai Dholaria, Jesús Berdeja, Ankit Kansagra

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Purpose of Review: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. Recent Findings: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. Summary: This review article addresses the present-day challenges and discusses opportunities to optimize the access and affordability of the CAR T-cell therapy. The field of cellular immunotherapy is going to change the future of solid tumors and non-oncological diseases. However, this promising therapy poses challenges in the administration and management of quality in the current field of healthcare. We describe various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies.

Original languageEnglish (US)
Pages (from-to)345-356
Number of pages12
JournalCurrent Hematologic Malignancy Reports
Volume16
Issue number4
DOIs
StatePublished - Aug 2021
Externally publishedYes

Keywords

  • Access
  • Acute lymphoblastic leukemia
  • Barriers
  • CAR T cell therapy
  • Cost-effectiveness
  • Immune-effector cell therapy
  • Immunotherapy
  • Lymphoma
  • Multiple myeloma
  • Quality

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments'. Together they form a unique fingerprint.

Cite this